Q2 2025 Vaxart Inc Earnings Call Transcript
Key Points
- Vaxart Inc (VXRT) reported a significant increase in revenue for Q2 2025, reaching $39.7 million compared to $6.4 million in Q2 2024, primarily due to a BAA contract.
- The company successfully enrolled approximately 5,000 participants in its COVID-19 Phase 2B trial, showcasing strong public interest in its oral vaccine platform.
- Positive top-line results from the Phase 1 trial of the second-generation norovirus vaccine constructs showed statistically significant increases in norovirus blocking antibodies.
- Vaxart Inc (VXRT) reported promising preclinical results for its avian influenza vaccine, demonstrating 100% protection against death in a ferret challenge model.
- The company is actively pursuing strategic partnerships and non-dilutive funding options to extend its cash runway and support ongoing and future clinical trials.
- Vaxart Inc (VXRT) received a second stop work order for its COVID-19 Phase 2B trial, halting further enrollment and creating uncertainty around trial continuation.
- The company's listing on NASDAQ has been suspended due to non-compliance with the $1 minimum bid price requirement, impacting its attractiveness to institutional investors.
- Progression of the norovirus program to Phase 2B is contingent on securing additional funding or partnerships, which introduces financial uncertainty.
- The company implemented a workforce reduction of approximately 21% in Q2 2025 to decrease operating costs, indicating financial pressures.
- Despite positive trial data, the company faces challenges in securing partnerships and funding, which are critical for advancing its vaccine programs.
Greetings and welcome to the Vaxart Business Update and second quarter 2025 financial results conference call. A question and answer session will follow management's opening remarks.
Individual investors may submit written questions to IR at https://vaxart.com/. As a reminder, this conference is being recorded.
I would now like to turn the webcast over to your host Ed Berg, senior Vice President and general counsel. Please go ahead.
Good afternoon and welcome to today's call.
Joining us from Vaxart are Steven Lo, Chief Executive Officer, Dr. Sean Tucker, founder and Chief Scientific Officer, Dr. James Cummings, Chief Medical Officer, and Jeroen Grasman, Chief Financial Officer.
Before we begin, I would like to remind everyone that during this conference call, Vaxart may make forward-looking statements, including statements about the company's financial results, financial guidance, its future business strategies and operations, and its product development and regulatory progress,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
